<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01906879</url>
  </required_header>
  <id_info>
    <org_study_id>201304017MINB</org_study_id>
    <nct_id>NCT01906879</nct_id>
  </id_info>
  <brief_title>Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection</brief_title>
  <official_title>Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Whether non-bismuth quadruple therapy (concomitant therapy) is more effective than bismuth
      quadruple therapy or triple therapy for 14 days remains unknown.

      Therefore, we aim to compare the eradication rates and long term re-infection rates of
      quadruple therapy for 10 days versus non-bismuth quadruple therapy for 10 days vs. triple
      therapy for 14 days.

      Methods: This will be a multi-center, open labeled, randomized control trial Patients: H.
      pylori infected patients who have willingness to receive eradication therapy

      Testing for H. pylori infection Before First Line Ttreatment

      (1)Any two positive of rapid urease test, histology, serology and culture or a positive UBT
      will be considered as H. pylori infected

      After First Line Treatment: C13-Urea breath test will be used to assess the existence of H.
      pylori 6-8 weeks after first line therapy.

      Long term reinfection: C13- Urea breath test will be used to assess the recurrence of H.
      pylori 1 year after eradication therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First line therapy: open labeled, randomized control trial, randomized into one of the three
      groups Group (A): triple therapy for 14 days D1-D14: (lansoprazole 30mg + clarithromycin
      500mg + amoxicillin 1gm) bid Group (B): non-bismuth quadruple therapy for 10 days D1-D10:
      lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg
      bid Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid +
      colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid

      Second line therapy: patients who fail from first line treatment will be rescue with the
      following treatment Group (A) Patient who fail from triple therapy will be retreated with
      bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth
      subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid Group (B) Patient who
      fail from non-bismuth quadruple therapy will be retreated with bismuth quadruple therapy for
      10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid +
      metronidazole 500mg tid + tetracycline 500mg tid Group (C) Patients who fail from bismuth
      quadruple therapy will be retreated with non-bismuth quadruple therapy for 10 days D1-D10:
      lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg
      bid
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate for H. pylori</measure>
    <time_frame>6 weeks</time_frame>
    <description>Eradication rate in the first line according to intention to treat (ITT) and per-protocol (PP) analysis in the three treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of each treatments</measure>
    <time_frame>2 weeks</time_frame>
    <description>(1) Incidence of adverse effects in the first line therapy in the three treatment groups</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reinfection rate</measure>
    <time_frame>1 year</time_frame>
    <description>Eradication rates in the second line treatment in the three treatment groups
Overall eradication rates after first line and second line treatment in the three treatment groups
Antibiotic resistance of gut flora after first line and second line treatments in the three treatment groups
Changes of gut microbiota in the three treatment groups
Re-infection rate one year after eradication therapy</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1620</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Triple therapy (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lansoprazole, 30mg, twice daily, for 14 days, po clarithromycin, 500mg, twice daily, for 14 days, po amoxicillin, 1gm, twice daily, for 14 days, po</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-bismuth quadruple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group (B): non-bismuth quadruple therapy for 10 days: lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bismuth quadruple therapy for 10 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triple, quadruple, non-bismuth quadruple therapy</intervention_name>
    <description>triple therapy, quadruple therapy, non-bismuth quadruple therapy</description>
    <arm_group_label>Triple therapy (A)</arm_group_label>
    <arm_group_label>non-bismuth quadruple therapy</arm_group_label>
    <arm_group_label>bismuth quadruple therapy for 10 days</arm_group_label>
    <other_name>Group (A): triple therapy for 14 days</other_name>
    <other_name>Group (B): non-bismuth quadruple therapy for 10 days</other_name>
    <other_name>Group (C): bismuth quadruple therapy for 10 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients aged greater than 20 years who have H. pylori infection without prior eradication
        therapy and are willing to receive the sequential therapy will be eligible for enrolment.
        Written informed consents will be obtained from all patients prior to enrollment.

        Exclusion Criteria:

        Patients will be excluded from the study if any one of the following criteria is present:
        (1) children and teenagers aged less than 20 years, (2) history of gastrectomy, (3)gastric
        malignancy, including adenocarcinoma and lymphoma, (4) previous allergic reaction to
        antibiotics (amoxicillin, clarithromycin, metronidazole, or levofloxacin) and prompt pump
        inhibitors (lansoprazole), (5)contraindication to treatment drugs, (6) pregnant or
        lactating women, (7) severe concurrent diseases, and (8) Patients who cannot give informed
        consent by himself or herself.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Shiang Wu, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyh-Ming Liou, MD, PhD</last_name>
    <email>dtmed046@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chiayi Christian Hospital</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Po-ye Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Hsinchu Branch</name>
      <address>
        <city>Hsinchu</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Fong Hsu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wen Fong Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>E- DA Hospital and I-Shou University</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-Yang Chang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chi Yang Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeng-Yih Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ming-Shiang Wu</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyh-Ming Liou, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ming-Shiang Wu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jyh-Ming Liou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mei-Jyh Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chien-Chun Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital, Taipei</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Hsiung Chang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wen-Hsiung Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Chao Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiing-Chyuan Luo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jiing-Chyuan Luo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital, Taitung</name>
      <address>
        <city>Taitung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Chung Bair, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ming Chung Bair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Yun-Lin County</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chieh-Chang Chen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chieh-Chang Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji-Yuh Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Jen Fang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chi-Yang Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2013</study_first_submitted>
  <study_first_submitted_qc>July 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2013</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

